Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
84.96
-0.22 (-0.26%)
Mar 23, 2026, 4:00 PM EDT - Market closed
Guardant Health Stock Forecast
Stock Price Forecast
The 20 analysts that cover Guardant Health stock have a consensus rating of "Strong Buy" and an average price target of $117.8, which forecasts a 38.65% increase in the stock price over the next year. The lowest target is $55 and the highest is $180.
Price Target: $117.8 (+38.65%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Guardant Health stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 8 | 7 | 7 |
| Buy | 15 | 15 | 13 | 12 | 12 | 12 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 23 | 23 | 21 | 21 | 20 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $120 → $130 | Buy | Maintains | $120 → $130 | +53.01% | Feb 24, 2026 |
| Leerink Partners | Leerink Partners | Buy Maintains $170 → $180 | Buy | Maintains | $170 → $180 | +111.86% | Feb 20, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $135 → $150 | Strong Buy | Maintains | $135 → $150 | +76.55% | Feb 20, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $125 → $135 | Strong Buy | Maintains | $125 → $135 | +58.90% | Feb 20, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $120 → $130 | Buy | Maintains | $120 → $130 | +53.01% | Feb 20, 2026 |
Financial Forecast
Revenue This Year
1.31B
from 982.02M
Increased by 33.40%
Revenue Next Year
1.68B
from 1.31B
Increased by 28.32%
EPS This Year
-2.78
from -3.32
EPS Next Year
-1.86
from -2.78
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.4B | 1.9B | |||
| Avg | 1.3B | 1.7B | |||
| Low | 1.2B | 1.5B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 39.0% | 46.9% | |||
| Avg | 33.4% | 28.3% | |||
| Low | 26.0% | 16.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -1.27 | 0.38 | |||
| Avg | -2.78 | -1.86 | |||
| Low | -3.11 | -2.61 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.